

**SUPPLEMENTARY TABLE 1. Estimated vaccination coverage by age 24 months\* among children born 2015-2016,† by selected vaccines and doses and race/ethnicity,§ National Immunization Survey-Child 2016-2018, United States**

Vaccine/Dose	Race/Ethnicity						
	White (referent) (n = 14,423) % (95% CI)	Black (n = 1,814) % (95% CI)	Hispanic (n = 5,468) % (95% CI)	American Indian/Alaska Native (n = 341) % (95% CI)	Asian (n = 1,064) % (95% CI)	Native Hawaiian or other Pacific Islander (n = 103) % (95% CI)	Multiple Race (n = 1,846) % (95% CI)
<b>DTaP¶</b>							
≥3 doses	94.3 (93.5-95.0)	92.7 (89.4-95.3)	93.5 (91.9-94.9)	88.5 (80.2-94.4)	95.5 (93.3-97.2)	89.3 (78.3-96.2)	93.2 (89.5-96.0)
≥4 doses	81.6 (80.1-82.9)	75.0 (71.1-78.7)**	79.7 (76.5-82.7)	67.7 (58.5-76.6)**	86.0 (80.0-90.9)	--††	81.4 (77.2-85.2)
<b>Poliovirus (≥3 doses)</b>	93.3 (92.4-94.0)	91.9 (88.6-94.6)	92.2 (90.4-93.7)	87.4 (79.1-93.6)	95.7 (93.3-97.4)**	87.9 (77.0-95.2)	91.4 (87.7-94.4)
<b>MMR (≥1 dose)§§</b>	89.5 (88.3-90.7)	89.4 (86.0-92.3)	91.4 (89.7-92.9)	85.2 (76.9-91.7)	94.7 (92.2-96.6)**	--††	91.6 (87.9-94.5)
<b>Hib¶¶¶</b>							
Primary series	93.3 (92.3-94.3)	92.0 (88.8-94.6)	92.4 (90.5-94.1)	85.4 (77.1-91.8)**	92.8 (87.7-96.3)	--††	92.0 (88.3-94.8)
Full series	80.8 (79.3-82.2)	74.9 (71.0-78.6)**	78.8 (75.6-81.8)	74.8 (65.9-82.9)	85.4 (79.8-90.1)	--††	80.1 (75.8-84.2)
<b>HepB</b>							
Birth dose***	72.1 (70.5-73.6)	75.9 (71.7-79.6)	78.2 (75.3-80.9)**	78.7 (70.1-85.4)	78.0 (71.5-83.4)	--††	78.4 (74.0-82.2)**
≥3 doses	91.1 (90.1-92.1)	89.6 (86.2-92.5)	91.4 (89.5-93.1)	88.5 (80.9-94.1)	92.3 (86.9-96.0)	90.1 (79.4-96.6)	91.1 (87.4-94.0)
<b>Varicella vaccine (≥1 dose)§§</b>	89.0 (87.7-90.2)	88.9 (85.4-91.9)	91.6 (90.0-93.1)**	85.4 (77.4-91.7)	93.7 (91.1-95.8)**	--††	90.8 (86.8-93.9)
<b>PCV</b>							
≥3 doses	92.6 (91.5-93.7)	91.3 (88.0-94.0)	91.6 (89.6-93.3)	85.6 (76.7-92.3)	91.0 (86.0-94.8)	88.1 (77.1-95.4)	91.8 (88.1-94.7)
≥4 doses	82.9 (81.4-84.3)	76.5 (72.7-80.1)**	80.4 (77.3-83.4)	68.2 (59.1-76.9)**	80.4 (74.1-86.0)	--††	81.9 (77.6-85.8)
<b>HepA</b>							
≥1 dose	82.9 (81.3-84.4)	83.1 (79.5-86.4)	87.7 (85.9-89.5)**	82.3 (74.0-89.1)	91.2 (87.9-94.0)**	--††	84.4 (78.8-89.1)
≥2 doses (by 35 months)	75.6 (73.3-77.7)	73.6 (67.8-79.1)	78.8 (74.8-82.6)	--††	86.1 (77.7-92.6)**	--††	72.6 (66.9-78.0)
<b>Rotavirus (by 8 months)†††</b>	77.9 (76.5-79.2)	64.9 (60.5-69.0)**	71.1 (67.6-74.3)**	63.5 (54.2-71.9)**	70.5 (62.9-77.1)	--††	73.6 (68.8-78.0)
<b>Influenza ≥2 doses§§§</b>	59.0 (57.3-60.7)	43.8 (39.8-48.1)**	55.0 (51.7-58.3)**	56.5 (47.7-65.7)	74.5 (68.0-80.5)**	--††	57.7 (52.2-63.4)
<b>Combined 7-vaccine series¶¶¶¶</b>	69.6 (67.8-71.3)	63.5 (59.5-67.6)**	68.0 (64.6-71.3)	61.0 (51.9-70.2)	72.3 (65.8-78.5)	--††	70.9 (66.1-75.5)
<b>No vaccinations</b>	1.6 (1.3-1.9)	--††	0.8 (0.5-1.1)**	--††	--††	--††	1.2 (0.7-2.0)

**Abbreviations:** CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.

\* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

† Data for the 2015 birth year are from survey years 2016, 2017, and 2018; data for the 2016 birth year are considered preliminary and come from survey years 2017 and 2018 (data from survey year 2019 are not yet available).

§ Children's race/ethnicity was reported by the parent or guardian. Children identified in this report as white, black, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races were reported by the parent or guardian as non-Hispanic. Children identified as being of multiple races had more than one race category selected. Children identified as Hispanic might be of any race.

¶ Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

\*\* Statistically significant (p<0.05) difference compared with the referent group.

†† Estimate not available because the unweighted sample size for the denominator was <30, or 95% CI half width/estimate >0.588, or 95% CI half-width was ≥10.

§§ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

¶¶ Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

\*\*\* One dose HepB administered from birth through age 3 days.

††† Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.

§§§ Doses must be at least 24 days apart (four weeks with a four-day grace period).

¶¶¶¶ The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of Varicella vaccine, and ≥4 doses of PCV.